Skip to main content

FDA stinks at policing conflicts

Just when you thought nobody could be worse than the National Institutes of Health at managing financial conflicts of interest among trial investigators... The Inspector General of the Department of Health and Human Services released a linkurl:report;https://www.oig.hhs.gov/oei/reports/oei-05-07-00730.pdf today that indicates a pretty severe lack of oversight over at the Food and Drug Administration. The report found that only one percent of the almost 27,000 clinical investigators contracted by

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Just when you thought nobody could be worse than the National Institutes of Health at managing financial conflicts of interest among trial investigators... The Inspector General of the Department of Health and Human Services released a linkurl:report;https://www.oig.hhs.gov/oei/reports/oei-05-07-00730.pdf today that indicates a pretty severe lack of oversight over at the Food and Drug Administration. The report found that only one percent of the almost 27,000 clinical investigators contracted by the agency in 2007 disclosed a financial interest. In 42% of clinical trials, the FDA never even received the financial disclosure forms from participating investigators that the agency mandates. The FDA not only failed to address these shortcomings, in 20% of the trials where investigators did report a financial conflict, the FDA took no action. In 31% of trials where researchers did submit financial conflict documentation, FDA reviewers didn't even indicate that they read the forms. If this isn't enough to make you smack your forehead and send your morning coffee spraying from one nostril, the FDA also apparently told the inspector general that it wasn't that interested in requiring drug makers to collect and report accurate financial disclosure information from investigators prior to the commencement of clinical trials. "FDA asserted that this additional effort would not be worthwhile because financial interests are only one form of potential bias," the report reads. All of this doesn't appear to be bothering potential clinical trial participants searching to wring a buck out of our foundering economy, though. The __Boston Globe__ linkurl:reported;https://www.boston.com/news/world/europe/articles/2009/01/05/paid_studies_draw_more_interest_in_sour_economy/?page=1 last week that the number of Americans seeking to become paid clinical trial subjects has skyrocketed since the economy went south.
**__Related stories:__***linkurl:Should conflicts mean no NIH grant?;https://www.the-scientist.com/blog/display/55058/
[29th September 2008]*linkurl:Report faults NIH on conflicts;https://www.the-scientist.com/blog/display/54183/
[18th January 2008]*linkurl:CSPI: FDA can manage conflicts better;https://www.the-scientist.com/blog/display/53953/
[3rd December 2007]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo